Symptoms and General Pathology

All Conditions

Neoplasms

Digestive System Diseases

Skin and Connective Tissue Diseases

Gland and Hormone Related Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Recurrence

Colorectal Neoplasms

Breast Neoplasms

Triple Negative Breast Neoplasms

Pancreatic Neoplasms

Sarcoma

Neoplasm Metastasis

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Colonic Neoplasms

Rectal Neoplasms

Gastrointestinal Stromal Tumors

Endometrial Neoplasms

Breast Diseases

Skin Diseases

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Endocrine Gland Neoplasms

Pancreatic Diseases

Endocrine System Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Uterine Neoplasms

Uterine Diseases

Neoplastic Processes

Pancreatic Cancer

Ovarian Cancer

Ovarian Epithelial Cancer

Soft Tissue Sarcoma

Antineoplastic Agents

All Drugs and Chemicals

Herbal and Botanical

Gemcitabine

Antimetabolites

Cola

Multiple oral doses of LY2880070 during 21-day cycles

Multiple oral doses of LY2880070, and Gemcitabine administered intravenously during 21-day cycles

Multiple oral doses of LY2880070 administered during 21 day cycles, to participants who are poor metabolizers

Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)

LY2880070

50 to 600 milligrams per square meter of body surface area (mg/m2)

Esperas Pharma Inc.

Temitope Oke

Prafull Ghatage

Trish Mhonde

Quincy Chu

Joanne Marshall

Yvette Drew

Horace Wong

Amit Oza

Alessandra Figueiredo de Vasconcelos

Wilson Miller

Lucy Gilbert

Mohamed Bakir

Diane Provencher

Sara Bilić Knežević

Prim. Višnja Matković

Bogdan Zurawski

Dagmara Klasa-Mazurkiewicz

Pawel Blecharz

Marek Jasiowka

Email: Darcy.Vincett@ozmosisresearch.ca

The main purpose of this 3-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumors.

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

A Phase 1b/2a Three-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer

Sarcoma, Ewing

Desmoplastic Small Round Cell Tumor

Osteosarcoma

Neoplasms, Bone Tissue

Neoplasms, Connective Tissue

Ewing Sarcoma

Participants have a diagnosis of Ewing sarcoma as molecularly defined by an EWSR1 fusion with an ETS-transcription factor family member including FLI1, ERG, ETV1, ETV4, and FEV

Patients will receive treatment in 21-day cycles with LY2880070 50 mg twice daily orally on days 2-6, 9-13, and 16-20

Participants will receive treatment in 21-day cycles with gemcitabine 100 mg/m2 intravenously on days 1, 8 and optionally on day 15

Emily Slotkin, MD

Viswatej Avutu, MD

The purpose of this study is to find out whether LY2880070 combined with the chemotherapy drug gemcitabine is an effective treatment for Ewing sarcoma or Ewing-like sarcoma.

A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor

A Phase II Study of Oral CHK1 Inhibitor LY2880070 in Combination With Low-Dose Gemcitabine in Patients With Relapsed or Refractory Ewing Sarcoma, Ewing-like Sarcoma, and Desmoplastic Small Round Cell Tumor

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

The ORR will include complete response and partial response (CR+PR) as defined using RECIST 1.1 criteria.

Memorial Sloan Kettering Cancer Center

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer	NCT02632448	Solid Tumors Colorectal Canc... Breast Cancer Ovarian Cancer Colon Cancer Rectal Cancer Neoplasms Endometrial Can... Soft Tissue Sar... Triple Negative... Pancreas Cancer Pancreatic Canc...	LY2880070 Gemcitabine	18 Years -	Esperas Pharma Inc.
A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor	NCT05275426	Ewing Sarcoma Ewing-Like Sarc...	LY2880070 Gemcitabine	-	Memorial Sloan Kettering Cancer Center
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer	NCT02632448	Solid Tumors Colorectal Canc... Breast Cancer Ovarian Cancer Colon Cancer Rectal Cancer Neoplasms Endometrial Can... Soft Tissue Sar... Triple Negative... Pancreas Cancer Pancreatic Canc...	LY2880070 Gemcitabine	18 Years -	Esperas Pharma Inc.
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer	NCT02632448	Solid Tumors Colorectal Canc... Breast Cancer Ovarian Cancer Colon Cancer Rectal Cancer Neoplasms Endometrial Can... Soft Tissue Sar... Triple Negative... Pancreas Cancer Pancreatic Canc...	LY2880070 Gemcitabine	18 Years -	Esperas Pharma Inc.

Spots Global Cancer Trial Database for ly2880070

Every month we try and update this database with for ly2880070 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for ly2880070

Every month we try and update this database with for ly2880070 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for ly2880070 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.